

Applicant : Samuel J. Shuster et al.
Serial No. : 10/500,449
Filed : December 3, 2004
Page : 2 of 2

Attorney's Docket No.: 14848-008US1

criteria of (B)(2) because all alternatives belong to the same art recognized class of compounds (i.e., antisense oligonucleotides), and each member could be substituted one for the other with the expectation that the same intended result would be achieved (i.e., inhibiting the production of P2X2). Thus, according to the guidelines set forth in Section (f)(i)(a) of Annex B of the PCT Administrative Instructions, the special technical feature as defined by PCT Rule 13.2 has been met.

Applicants submit that the further restriction of the claims of Group I is improper, and respectfully request that the further restriction of Group I be withdrawn and the P2X2 nucleic acid sequence be examined with respect to all of the recited accessible regions.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

/August 1, 2008/

/M. Angela Parsons/

Date: _____

M. Angela Parsons, Ph.D.
Reg. No. 44,282

Fish & Richardson P.C.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (877) 769-7945